Fig. 3: Imaging omics for the changing of participants on CT and PET/CT between 2 common mutant subtypes. | Nature Communications

Fig. 3: Imaging omics for the changing of participants on CT and PET/CT between 2 common mutant subtypes.

From: Neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancer: a single-arm phase II trial

Fig. 3

The trend of radiological changes in (a) TLD via CT (Ex19-Del, n = 22; Ex21-L858R, n = 27), (c) PT-S via PET-CT (Ex19-Del, n = 7; Ex21-L858R, n = 15) in paired participants pre- and post-treatment between 2 common mutant subtypes. The degree of radiological changes in (b) TLD via CT (Ex19-Del, n = 22; Ex21-L858R, n = 27), (d) PT-S via PET-CT (Ex19-Del, n = 7; Ex21-L858R, n = 15) in participants pre- and post-treatment between 2 common mutant subtypes. Centers, boxes, whiskers, and dots indicate medians, quantiles, minima/maxima, and outliers, respectively. For difference comparisons in matched samples (a and c), two-sided paired Wilcoxon test was used. For difference comparisons in two independent samples (b and d), two-sided unpaired Wilcoxon test was used. TLD: target-lesions dimension; PT-S: primary tumor SUVmax. Source data are provided as a Source Data file.

Back to article page